A 52-years-old lady was incidentally detected to have pancytopenia during in-hospital evaluation of unexplained fever. On evaluation, she was diagnosed as cytogenetically normal acute myeloid leukaemia (AML) with maturation (FLT3/ITD, NPM1 mutation positive). She was managed with decitabine @ 20 mg/m 2 /day for 5 days. She developed skin lesions on day 2 of therapy over the arms/trunk (Fig. 1a-d) . The skin biopsy of the lesions was suggestive of Sweet's syndrome (Fig. 2) . She was initially managed with Prednisolone 1 mg/kg/day for 1 week with only partial improvement, followed by intravenous immunoglobulins (IVIG-2 g/kg over 2 days) with resolution of lesions ( Fig. 3a-d ). Within 2 months the patient developed recurrence of similar lesions on face/arms (Fig. 4) . AML was in remission with no evidence of relapse/progression at the time of reappearance of skin lesions. Repeat biopsy of the lesions again diagnosed as Sweet's syndrome (Fig. 5) , which was re-treated with IVIG (2 g/kg over 2 days) following which her lesions remitted (Fig. 6 ).
Sweet's syndrome, also known as acute febrile neutrophilic dermatosis occurs in three forms: classical, malignancy-associated and drug-related. Malignancy associated Sweet's syndrome may occur in one of the three settings, either as paraneoplastic syndrome or drug-induced dermatosis (ATRA/bortezomib/Cytarabine/G-CSF/imatinib) or concurrently with leukaemia cutis [1] . AML and MDS are common hematological disorders associated with Sweet's syndrome. Recurrence is commonly seen in MDS (particularly lymphocytic variant) and when seen in AML, it temporally relates to relapse/progression [1, 2] . Management includes treating the underlying cause, systemic steroids (Ist line agents) or indomethacin, clofazamine, dapsone and cyclosporine (IInd line agents) [3] .
In our case interestingly, recurrence of sweet's syndrome was neither secondary to progression nor relapse of AML. We reemphasise role of IVIG in refractory/relapsed Sweet's syndrome
Learning Points
• Malignancy associated Sweet's syndrome in haematology is commonly associated with AML, MDS.
• Recurrent Sweet's syndrome is a feature of myelodysplasia.
• IVIG is one of the treatment options to recalcitrant Sweet's syndrome. Informed Consent Informed consent was obtained from the participant included in the study. 
